Search results for "Chronic bronchiti"

showing 10 items of 33 documents

Asthma control in elderly asthmatics. An Italian observational study

2014

SummaryBackgroundThe exponential increase of individuals aged >64 yrs is expected to impact the burden of asthma. We aimed to explore the level of asthma control in elderly subjects, and factors influencing it.MethodsA multicenter observational study was performed on consecutive patients >64 years old with a documented physician-diagnosis of asthma. Sixteen Italian centers were involved in this 6-month project.FindingsA total of 350 patients were enrolled in the study. More than one-third of elderly asthmatic patients, despite receiving GINA step 3–4 antiasthmatic therapy, had an Asthma Control Test score ≤19, with a quarter experiencing at least one severe asthma exacerbation in the previo…

MalePulmonary and Respiratory MedicineChronic ObstructiveChronic bronchitismedicine.medical_specialtyExacerbationVital CapacitySettore MED/10 - Malattie Dell'Apparato Respiratorioelderly patientsPulmonary DiseasePulmonary Disease Chronic ObstructiveFEV1/FVC ratioElderlyForced Expiratory VolumeInternal medicinemedicineHumansAnti-Asthmatic AgentsAsthma control testAsmaAgedAsthmaCOPDAsma; elderly patientsAsthma; Asthma control test; Elderly; Aged; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Humans; Male; Pulmonary Disease Chronic Obstructive; Treatment Outcome; Vital Capacitybusiness.industryOverlap syndromemedicine.diseaseAsthma control test; Elderly; AsthmaAsthmarespiratory tract diseasesTreatment OutcomeSalbutamolPhysical therapyFemaleObservational studybusinessmedicine.drug
researchProduct

Upregulation of basic fibroblast growth factor in smokers with chronic bronchitis

2006

The aim of the study was to investigate the expression of basic fibroblast growth factor (bFGF) and its receptor, fibroblast growth factor receptor (FGFR)-1, in the central airways of smokers with chronic bronchitis. The lobar bronchi from 17 subjects undergoing thoracotomy for solitary nodules were examined. All had a history of cigarette smoking, nine had symptoms of chronic bronchitis and airflow limitation, and eight were asymptomatic with normal lung function. Using immunohistochemical methods, bFGF and FGFR-1 expression in the total airway wall and the different airway compartments, i.e. bronchial glands, submucosal vessels and smooth muscle, was quantified. Moreover, to investigate t…

MalePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyChronic bronchitisAngiogenesisBasic fibroblast growth factorFibroblast growth factorchemistry.chemical_compoundGrowth factor receptorCigarette smokingHumansMedicineAgedFibrolast growth factor receptor-1business.industryChronic obstructive pulmonary diseaseFibroblast growth factor receptor 1Smokingrespiratory systemmedicine.diseaseAirway remodelling; cigarette smoking; chronic obstructive pulmonary disease; fibroblast growth factor receptor-1Airway remodellingUp-Regulationrespiratory tract diseasesBronchitis ChronicchemistryFibroblast growth factor receptorBronchitisFemaleFibroblast Growth Factor 2Airway remodelling; Chronic obstructive pulmonary disease; Cigarette smoking; Fibrolast growth factor receptor-1;business
researchProduct

CAT in COPD phenotypes (POPE study)

2016

Background: The COPD assessment test (CAT) is widely used for basic symptom evaluation in patients with COPD. The impact of COPD phenotypes on symptom scores using the CAT, however, remains largely unknown. Methods: The POPE-Study (NCT02119494) is an international, multicentre, observational cross-sectional survey of consecutive patients with COPD in Central and Eastern Europe (CEE). Respiratory symptoms using the modified Medical Research Council (mMRC) dyspnoea scale, and the CAT were recorded. Inclusion criteria: age ≥ 40 years, smoking history ≥ 10 pack-years, post-bronchodilator (BD) FEV1/FVC Results: 3366 COPD subjects (66 ± 8.8 yrs, post-BD FEV1 52.8 ± 18.5 % predicted, CAT 17.4 ± 7.…

Pediatricsmedicine.medical_specialtyCOPDChronic bronchitisbusiness.industryOverlap syndromemedicine.diseaseSmoking historyrespiratory tract diseases3. Good healthFEV1/FVC ratioInternal medicinemedicineCopd assessment testIn patient10. No inequalitybusiness5.2 Monitoring Airway Disease
researchProduct

LATE-BREAKING ABSTRACT: Phenotypes of COPD in central and Eastern Europe - The POPE study

2015

Introduction: Chronic obstructive pulmonary disease (COPD) represents a major health problem in Central and Eastern European (CEE) countries. However, data regarding symptom load and clinical phenotypes of patients with COPD in CEE remain largely unknown. Methods: Participation in the POPE Study (a multicentre, observational cross-sectional survey) was offered to consecutive outpatients with stable COPD in 11 CEE countries if they fulfilled the following criteria: age ≥ 40 years, smoking history ≥ 10 pack-years, post-bronchodilator (BD) FEV 1 /FVC Results: 3504 patients (66 ± 8.7 yrs, 69% male, post-BD FEV 1 53.0 ± 17.5% predicted, Charlson comorbidity index 2.0 ± 1.4, and 1.2 ± 1.6 exacerb…

Pediatricsmedicine.medical_specialtyCOPDeducation.field_of_studyChronic bronchitisbusiness.industryPopulationOverlap syndromemedicine.diseaserespiratory tract diseases3. Good healthEastern europeanFEV1/FVC ratioCharlson comorbidity indexmedicineObservational studybusinesseducation1.1 Clinical Problems
researchProduct

Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstruct…

1998

Abstract The aims of management in mild-to-moderate stable chronic obstructive pulmonary disease (COPD) are to improve symptoms and quality of life (QOL), reduce decline in lung function, prevent and treat complications, increase survival while maintaining QOL, and minimize the adverse effects of treatment. Bronchodilator therapy is the keystone of improving COPD symptoms and functional capacity. The primary objective of this open-label study was to compare the efficacy and tolerability of salmeterol 50 μg BID administered by metered-dose inhaler versus oral, titrated, sustained-release theophylline BID, both given for 3 months to patients with a clinical history of chronic bronchitis. The …

PharmacologyCOPDChronic bronchitismedicine.drug_classbusiness.industrymedicine.diseaseTolerabilityBronchodilatorAnesthesiamedicineSalbutamolPharmacology (medical)TheophyllineSalmeterolAdverse effectbusinessmedicine.drugClinical Therapeutics
researchProduct

Long-term residential exposure to air pollution and risk of chronic respiratory diseases in Italy: The BIGEPI study

2023

: Long-term exposure to air pollution has adverse respiratory health effects. We investigated the cross-sectional relationship between residential exposure to air pollutants and the risk of suffering from chronic respiratory diseases in some Italian cities. In the BIGEPI project, we harmonised questionnaire data from two population-based studies conducted in 2007-2014. By combining self-reported diagnoses, symptoms and medication use, we identified cases of rhinitis (n = 965), asthma (n = 328), chronic bronchitis/chronic obstructive pulmonary disease (CB/COPD, n = 469), and controls (n = 2380) belonging to 13 cohorts from 8 Italian cities (Pavia, Turin, Verona, Terni, Pisa, Ancona, Palermo,…

Public healthEnvironmental EngineeringPublic health.EpidemiologySettore MED/10 - Malattie Dell'Apparato RespiratorioPollutionAsthmaAir quality; Asthma; Chronic bronchitis; Epidemiology; Public health; RhinitisChronic bronchitiChronic bronchitisAir qualityEnvironmental ChemistryWaste Management and DisposalRhinitis
researchProduct

Phenotypes contribute to treatments.

2017

Chronic obstructive pulmonary disease (COPD) represents a major health problem in Central and Eastern European (CEE) countries; however, there are no data regarding clinical phenotypes of these patients in this region. Participation in the Phenotypes of COPD in Central and Eastern Europe (POPE) study was offered to stable patients with COPD in a real-life setting. The primary aim of this study was to assess the prevalence of phenotypes according to predefined criteria. Secondary aims included analysis of differences in symptom load, comorbidities and pharmacological treatment. 3362 patients with COPD were recruited in 10 CEE countries. 63% of the population were nonexacerbators, 20.4% frequ…

Pulmonary and Respiratory MedicineChronic bronchitismedicine.medical_specialtyExacerbation1InflammationDisease03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineInternal medicinemedicineHumansCOPD030212 general & internal medicineCOPDbusiness.industryOriginal Articlesmedicine.diseasePhenotypeObstructive lung diseaserespiratory tract diseasesPhenotype030228 respiratory systemImmunologymedicine.symptomAirwaybusinessThe European respiratory journal
researchProduct

TLR4 Up-regulation and Reduced Foxp3 Expression in Mechanically Ventilated Smokers with Obstructive Chronic Bronchitis

2013

Background: Chronic bronchitis (CB) is a risk factor in chronic obstructive pulmonary disease (COPD) for accelerated lung function decline and increased mortality. The lung and systemic inflammatory and immunological profile of COPD patients with CB which acutely experience respiratory failure upon a disease exacerbation is unknown. Methods: In this study, we explored the expression of Foxp3 by western blot analysis, TLR4 by immunocytochemistry and the concentrations of IP-10 and IL-8 by ELISA in the mini-bronchoalveolar lavages (mini-BAL) and in the peripheral blood of patients with respiratory failure requiring intubation and mechanical ventilation. The recruited subjects were separated i…

Pulmonary and Respiratory MedicineMaleChronic bronchitismedicine.medical_specialtyPathologyNeutrophilsmedicine.medical_treatmentSettore MED/41 - AnestesiologiaGastroenterologyStatistics NonparametricLeukocyte CountPulmonary Disease Chronic ObstructiveAcute Lung InjuryToll-like receptors Foxp3 Chemokines Smokers Respiratory failureInternal medicineMedicineHumansRisk factorAgedMechanical ventilationAged 80 and overCOPDLungbusiness.industryInterleukin-8SmokingFOXP3Forkhead Transcription Factorsmedicine.diseaseRespiration Artificialrespiratory tract diseasesUp-RegulationBronchitis ChronicChemokine CXCL10Toll-Like Receptor 4medicine.anatomical_structureRespiratory failureBronchitisFemalebusinessBronchoalveolar Lavage Fluid
researchProduct

Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study.

2017

Chronic obstructive pulmonary disease (COPD) represents a major health problem in Central and Eastern European (CEE) countries; however, there are no data regarding clinical phenotypes of these patients in this region.Participation in the Phenotypes of COPD in Central and Eastern Europe (POPE) study was offered to stable patients with COPD in a real-life setting. The primary aim of this study was to assess the prevalence of phenotypes according to predefined criteria. Secondary aims included analysis of differences in symptom load, comorbidities and pharmacological treatment.3362 patients with COPD were recruited in 10 CEE countries. 63% of the population were nonexacerbators, 20.4% frequen…

Pulmonary and Respiratory MedicineMalePediatricsmedicine.medical_specialtyChronic bronchitisCross-sectional studyInternational CooperationPopulationVital CapacityComorbidity03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineForced Expiratory VolumemedicinePrevalenceHumans030212 general & internal medicineeducationBronchitisAgededucation.field_of_studyCOPDbusiness.industryData CollectionSmokingTobacco Use DisorderMiddle Agedmedicine.diseaseComorbidityrespiratory tract diseases3. Good healthEastern europeanBronchitis ChronicEuropeCross-Sectional StudiesPhenotypeTreatment Outcome030228 respiratory systemCohortBronchitisFemalebusinessThe European respiratory journal
researchProduct

Tiotropium + olodaterol in patients with moderate to severe COPD with chronic bronchitis and/or emphysema

2017

Introduction: Chronic bronchitis and emphysema are two COPD phenotypes that can affect pharmacologic treatment decisions. Aims: Tiotropium (T) + olodaterol (O) was established for COPD treatment in two large Phase III trials. This post hoc analysis assessed the effect of T+O on lung function, symptoms and health-related quality of life (QoL) in patients (pts) with investigator-defined bronchitis and/or emphysema. Methods: TONADO ® 1+2 were replicate, randomised, double-blind, parallel-group trials. Pts with GOLD 2–4 COPD were randomised to once-daily T+O 2.5/5 or 5/5 µg, T 2.5 or 5 µg, or O 5 µg via Respimat ® inhaler. 1 End points included forced expiratory volume in 1 second (FEV 1 ) area…

Pulmonary and Respiratory MedicineModerate to severeChronic bronchitismedicine.medical_specialtyRespimatPhysiologyGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineIn patientRespiratory systemCOPDbusiness.industryInhalerOlodaterolArea under the curveTiotropium-olodaterolmedicine.diseaserespiratory tract diseasesSurgerychemistry030220 oncology & carcinogenesisBronchitisbusiness030217 neurology & neurosurgeryPneumologie
researchProduct